<h4>Purpose</h4>Cyclin-dependent kinase (CDK) 4/6 inhibitors have transformed the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, yet resistance remains common. This evidence concerns the gene ERBB2 and breast cancer.